Pharmacokinetic analysis of topical tobramycin in equine tears by automated immunoassay

BMC Veterinary Research

Renaud Léguillette²  Brian Skorobohach³  Andrew W Lyon¹  Sarah L Czerwinski² 

[1] Calgary Laboratory Services, Calgary, AB, Canada;Department of Veterinary Clinical and Diagnostic Sciences, Faculty of Veterinary Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada;Calgary Animal Referral and Emergency Centre, Calgary, AB, Canada

关键词: Ophthalmology;    Topical;    Tobramycin;    Tear;    Pharmacokinetics;    Equine;    Antibiotic;   

Others  :  1119746
DOI  :  10.1186/1746-6148-8-141

 received in 2012-03-28, accepted in 2012-08-14,  发布年份 2012

【 摘 要 】

Background

Ophthalmic antibiotic therapy in large animals is often used empirically because of the lack of pharmacokinetics studies. The purpose of the study was to determine the pharmacokinetics of topical tobramycin 0.3% ophthalmic solution in the tears of normal horses using an automated immunoassay analysis.

Results

The mean tobramycin concentrations in the tears at 5, 10, 15, 30 minutes and 1, 2, 4, 6 hours after administration were 759 (±414), 489 (±237), 346 (±227), 147 (±264), 27.6 (±28.4), 14.8 (±66.6), 6.7 (±18.6), and 23.4 (±73.4) mg/L. Mean tobramycin concentration was maintained above the MIC₉₀ for commonly isolated bacteria for 68.5 min.

Conclusion

A single dose of topical tobramycin resulted in therapeutic concentrations of tobramycin in the tears for 1 h after administration. Therapeutic levels of tobramycin remained in equine tears 6 times longer than was reported in rabbit tears.

【 授权许可】

   
2012 Czerwinski et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

【 参考文献 】

• [1]Clode AB: Therapy of equine infectious keratitis: a review. Equine Vet J 2010, 42(Suppl 37):19-23.
• [2]Keller RL, Hendrix DV: Bacterial isolates and antimicrobial susceptibilities in equine bacterial ulcerative keratitis (1993–2004). Equine Vet J 2005, 37(3):207-211.
• [3]Lee EJ, Truong TN, Mendoza MN, Fleiszig SM: A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics. Curr Eye Res 2003, 27(5):289-299.
• [4]Sauer P, Andrew SE, Lassaline M, Gelatt KN, Denis HM: Changes in antibiotic resistance in equine bacterial ulcerative keratitis (1991–2000): 65 horses. Vet Ophthalmol 2003, 6(4):309-313.
• [5]Wada S, Hobo S, Niwa H: Ulcerative keratitis in thoroughbred racehorses in Japan from 1997 to 2008. Vet Ophthalmol 2010, 13(2):99-105.
• [6]Brooks D: Corneal ulceration. In Ophthalmology for the equine practitioner. 2nd edition. Edited by Jackson D. Teton New Media, WY; 2008:86-111.
• [7]Le Goffic F, Capmau ML, Tangy F, Baillarge M: Mechanism of action of aminoglycoside antibiotics. Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits. Eur J of Biochem / FEBS 1979, 102(1):73-81.
• [8]Hendrix DV, Cox SK: Pharmacokinetics of topically applied ciprofloxacin in tears of mesocephalic and brachycephalic dogs. Vet Ophthalmol 2008, 11(1):7-10.
• [9]Hendrix DV, Stuffle JL, Cox SK: Pharmacokinetics of topically applied ciprofloxacin in equine tears. Vet Ophthalmol 2007, 10(6):344-347.
• [10]Richman J, Zolezio H, Tang-Liu D: Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms. Antimicrob Agents Chemother 1990, 34(8):1602-1604.
• [11]Tang-Liu DD, Schwob DL, Usansky JI, Gordon YJ: Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes. Clin Pharmacol Ther 1994, 55(3):284-292.
• [12]Osato MS, Jensen HG, Trousdale MD, Bosso JA, Borrmann LR, Frank J, Akers P: The comparative in vitro activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates. Am J Ophthalmol 1989, 108(4):380-386.
• [13]Chen T, Ward DA: Tear volume, turnover rate, and flow rate in ophthalmologically normal horses. Am J Vet Res 2010, 71(6):671-676.
• [14]Dodam JR, Branson KR, Martin DD: Effects of intramuscular sedative and opioid combinations on tear production in dogs. Vet Ophthalmol 1998, 1(1):57-59.
• [15]Brightman AH 2nd, Manning JP, Benson GJ, Musselman EE: Decreased tear production associated with general anesthesia in the horse. J Am Vet Med Assoc 1983, 182(3):243-244.
• [16]Hubenov H, Bakalov D, Krastev S, Yanev S, Haritova A, Lashev L: Pharmacokinetic studies on tobramycin in horses. J Vet Pharmacol Ther 2007, 30(4):353-357.
• [17]Shrivastava S, Shukla S, Dwivedi V, Chaudhary M: Comparative Antimicrobial Activity of Ceftazidime, Tobramycin and their Novel Fixed Dose Combination in Some Pathogenic Microorganisms. Curr Drug ther (serial online) 2009, 4(2):148-151.
• [18]Moore CP, Collins BK, Fales WH: Antibacterial susceptibility patterns for microbial isolates associated with infectious keratitis in horses: 63 cases (1986–1994). J Am Vet Med Assoc 1995, 207(7):928-933.
• [19]Gilbert ML, Wilhelmus KR, Osato MS: Comparative bioavailability and efficacy of fortified topical tobramycin. Investig Ophthalmol Vis Sci 1987, 28(5):881-885.
• [20]Scoper SV, Kabat AG, Owen GR, Stroman DW, Kabra BP, Faulkner R, Kulshreshtha AK, Rusk C, Bell B, Jamison T, et al.: Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension. Adv Ther 2008, 25(2):77-88.
• [21]Hendrix DV, Ward DA, Barnhill MA: Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture. Am J Vet Res 2001, 62(10):1664-1669.
• [22]Westermeyer HD, Hendrix DV, Ward DA, Cox SK: Tear, cornea, and aqueous humor concentrations of ciprofloxacin and moxifloxacin after topical ocular application in ophthalmologically normal horses. Am J Vet Res 2011, 72(3):398-403.
• [23]Scotty NC, Brooks DE, Schuman Rose CD: In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses. Am J Vet Res 2008, 69(1):101-107.